" class="no-js "lang="en-US"> Azafaros Archives - Medtech Alert
Thursday, March 28, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients

Azafaros has announced that the first patient has been enrolled in its Phase 2 RAINBOW […]

Azafaros Appoints Chief Operating Officer and Head of Finance

Azafaros today announced two appointments to their executive management team with Silvia Ragno, PhD, joining […]

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA

Azafaros today announced its progress in ongoing interactions with Health Authorities regarding its lead drug […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more